Microbiome in specific diseases
Emerging Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease: From Composition to Function
Section snippets
Methods for Gut Microbiome Profiling
Advances in profiling and analytic techniques are transforming microbiome research and have been recently reviewed elsewhere,5, 6 so we limit our discussion to an overview of methods that have been used in human studies in NAFLD (Figure 1). To date, most studies have used culture-independent, biomarker-based profiling techniques. This method involves sequencing a ubiquitous gene, which is represented by the 16S ribosomal RNA (16S rRNA) gene in bacteria. Biomarker-based profiling techniques
Human Gut Microbiome Profiles in Clinical Phenotypes of Nonalcoholic Fatty Liver Disease: Community Composition
Numerous human studies have demonstrated an association between gut dysbiosis and the spectrum of NAFLD in children7, 8, 9, 10 and adults.11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 All except 1 of these studies were cross-sectional,12 and most used biomarker-based sequencing to profile the gut microbiome. We review gut microbiome profiles, with a focus on genus-level differences, in the following clinical phenotypes: nonalcoholic fatty liver (NAFL), nonalcoholic steatohepatitis (NASH),
Human Gut Microbiome Profiles in Clinical Phenotypes of Nonalcoholic Fatty Liver Disease: Functional Potential
Several human studies have used “omics” techniques and thus added new perspectives on functional attributes of the gut microbiome in NAFL-, NASH-, and NAFLD-related advanced fibrosis.7, 8, 9, 11, 13, 17, 18, 21, 22 Results from fecal and serum metabolite profiling are listed in Table 1. To date, no human studies have functionally profiled the gut microbiome in NAFLD-related HCC.
Postulated Mechanisms Linking the Gut Microbiome to Nonalcoholic Fatty Liver Disease
Although human studies have yielded insight into functional attributes of the gut microbiota in NAFLD, much of the mechanistic evidence linking the gut microbiome and NAFLD pathogenesis has been obtained from experiments in animal models. We summarize the current evidence for postulated microbiome-associated mechanisms contributing to the pathogenesis of NAFLD (Figure 2).
The Gut Microbiome and Nonalcoholic Fatty Liver Disease: From Research to Bedside
Microbiome-targeted therapy (MTT) is considered to include antibiotics, probiotics (culture of living microorganisms that could have health benefits for the human host), prebiotics (fermentable dietary fibers that stimulate the growth and survival of probiotics), synbiotics (combination of probiotics and prebiotics), and FMT.1 High-quality, large-scale clinical interventional trials examining MTT in NAFLD are lacking. Several randomized controlled trials have examined the use of non-FMT MTT in
Conclusions
In summary, preclinical evidence supports a causal role of gut microbiome in liver disease progression in NAFLD. However, there is much that is not understood about the gut-liver axis. Because of the cross-sectional nature of published human data, along with methods used for microbial profiling, most clinical evidence supports an association between dysbiosis and NAFLD, but mechanistic links have not been well established. Further well-designed, longitudinal, prospective cohort studies with
References (82)
- et al.
Interactions between the intestinal microbiome and liver diseases
Gastroenterology
(2014) - et al.
Gut microbiota dysbiosis in patients with non-alcoholic fatty liver disease
Hepatobiliary Pancreat Dis Int
(2017) - et al.
Gut microbiome composition in lean patients with NASH is associated with liver damage independent of caloric intake: a prospective pilot study
Nutr Metab Cardiovasc Dis
(2018) - et al.
Profile of gut microbiota associated with the presence of hepatocellular cancer in patients with liver cirrhosis
Transplant Proc
(2016) - et al.
Antibiotics protect against fructose-induced hepatic lipid accumulation in mice: role of endotoxin
J Hepatol
(2008) - et al.
Regulation of obesity-related insulin resistance with gut anti-inflammatory agents
Cell Metab
(2015) - et al.
JKB-121 in patients with nonalcoholic steatohepatitis: a phase 2 double blind randomized placebo control study
J Hepatol
(2018) - et al.
Association between composition of the human gastrointestinal microbiome and development of fatty liver with choline deficiency
Gastroenterology
(2011) - et al.
Microbial metabolites in health and disease: Navigating the unknown in search of function
J Biol Chem
(2017) - et al.
Insulin-type fructans modulate intestinal Bifidobacterium species populations and decrease fecal short-chain fatty acids in obese women
Clin Nutr
(2015)
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
Lancet
The human intestinal microbiome in health and disease
N Engl J Med
The gut microbiome and liver cancer: mechanisms and clinical translation
Nat Rev Gastroenterol Hepatol
Restoration of a healthy intestinal microbiota normalizes portal hypertension in a rat model of nonalcoholic steatohepatitis
Hepatology
Current understanding of the human microbiome
Nat Med
Best practices for analysing microbiomes
Nat Rev Microbiol
Characterization of gut microbiomes in nonalcoholic steatohepatitis patients: a connection between endogenous alcohol and NASH
Hepatology
Altered gut microbial energy and metabolism in children with non-alcoholic fatty liver disease
FEMS microbiology ecology
Gut microbiota profiling of pediatric nonalcoholic fatty liver disease and obese patients unveiled by an integrated meta-omics-based approach
Hepatology
Bifidobacteria and lactobacilli in the gut microbiome of children with non-alcoholic fatty liver disease: which strains act as health players?
Arch Med Sci
Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease
Clin Gastroenterol Hepatol
Molecular characterization of the fecal microbiota in patients with nonalcoholic steatohepatitis: a longitudinal study
PloS One
Bile acids and dysbiosis in non-alcoholic fatty liver disease
PloS One
The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota
Hepatology
Altered fecal microbiota correlates with liver biochemistry in nonobese patients with non-alcoholic fatty liver disease
Sci Rep
Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease
Cell Metab
Nonalcoholic fatty liver disease is associated with dysbiosis independent of body mass index and insulin resistance
Sci Rep
Hepatocellular carcinoma is associated with gut microbiota profile and inflammation in non-alcoholic fatty liver disease
Hepatology
Molecular phenomics and metagenomics of hepatic steatosis in non-diabetic obese women
Nat Med
Novel link between gut-microbiome derived metabolite and shared gene-effects with hepatic steatosis and fibrosis in NAFLD
Hepatology
Dysbiosis gut microbiota associated with inflammation and impaired mucosal immune function in intestine of humans with non-alcoholic fatty liver disease
Sci Rep
Obesity-associated gut microbiota is enriched in Lactobacillus reuteri and depleted in Bifidobacterium animalis and Methanobrevibacter smithii
Int J Obes
Connection between BMI-related plasma metabolite profile and gut microbiota
J Clin Endocrinol Metab
Akkermansia muciniphila inversely correlates with the onset of inflammation, altered adipose tissue metabolism and metabolic disorders during obesity in mice
Sci Rep
A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice
Nat Med
Human gut microbes impact host serum metabolome and insulin sensitivity
Nature
An integrated catalog of reference genes in the human gut microbiome
Nat Biotechnol
Extensive impact of non-antibiotic drugs on human gut bacteria
Nature
Proton pump inhibitors alter the composition of the gut microbiota
Gut
Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota
Nature
The gut mycobiome of the Human Microbiome Project healthy cohort
Microbiome
Cited by (0)
-
Conflicts of interest The authors disclose no conflicts.
-
Funding The authors disclose the following: Suzanne Sharpton is supported by the National Research Service Award (2T32DK060414-16) from the National Institute of Diabetes and Digestive and Kidney Diseases. Veeral Ajmera is supported by the Advanced/Transplant Hepatology Fellowship and the Alan Hofmann Clinical and Translational Research Award from the AASLD Foundation. Rohit Loomba is supported by National Institutes of Health (R01-DK106419-02).